Hcc1806

Archival FFPE tumor tissues were obtained from 195 ovarian and breast cancer patients who had signed the informed consents, and the study was approved by the Institutional Review Board of BGI Co., Ltd. 17 human cancer cells (HCC38, HCC1428, HCC1143, HCC1806, MX-1, HCC70, ZR-75-1, MDA-MB-453, MDA-MB-231, MDA-MB-361, MDA-MB-415, ZR-75-30, HS-578T, IGR-OV1, A2780, NCI/ADR-RES and OVCAR-4) and 3 matched-wildtype cell lines (HCC38BL, HCC1143BL and HCC1428BL) were purchased from the CoBioer Biosciences Co., Ltd. All cell lines have been verified by STR and were provided in the form of DNA status.

NCI-N87 (human gastric carcinoma), BxPC-3 (human pancreas adenocarcinoma), and Calu-3 (human non-small cell lung cancer) were purchased from ATCC (American Type Culture Collection). Both HCC1806 (human breast adenocarcinoma) and NCI-H23 (human non-small cell lung cancer) were purchased from CoBioer (Nanjing, China). The TROP2-overexpressing NCI-H23 (TROP2+) line, which is a subtype of NCI-H23 and constructed by Kelun-Biotech, and other cell lines, including NCI-N87, BxPC-3, HCC1806, and CI-H23 (parental), were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS). Calu-3 cells were cultured in Minimum Essential Medium (MEM) supplemented with 10% FBS and non-essential amino acids. All cell lines were maintained at 37°C in 5% CO₂. All the cell lines were examined by short tandem repeat authentication via Genegle (Chengdu, China) and tested for mycoplasma using a mycoplasma detection kit (Yise, Shanghai, China).